GSK to acquire IDRx
GSK Plc is to pay $1 billion upfront and potentially $150 million in milestone payments for IDRx Inc of the US which has an early clinical stage product for the treatment of gastrointestinal stromal tumours (GIST). The deal was announced at the start of the JP Morgan Healthcare Conference in San Francisco, US, on 13 January. It marks a significant expansion of the UK company’s portfolio.